Total trials
735
Active
149
Phase 3
28
Total enrollment
319,652
Pipeline matrix
Showing 40 of 51 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Carvedilol | — | — | — | — | — | 2 | |
| Diphenhydramine | — | — | — | — | — | 2 | |
| Treatment with oral sucrosomial iron | — | — | — | — | — | 1 | |
| Treatment with intravenous iron | — | — | — | — | — | 1 | |
| Metoprolol Succinate | — | — | — | — | — | 1 | |
| Bupropion Hydrochloride Controlled-release | — | — | — | — | — | 1 | |
| Cyclophosphamide | — | — | — | — | 5 | ||
| Prednisone | — | — | — | — | 3 | ||
| Methylene Blue | — | — | — | — | 3 | ||
| Lipid Emulsion | — | — | — | — | — | 2 | |
| Doxorubicin | — | — | — | — | — | 2 | |
| Pregabalin | — | — | — | — | 2 | ||
| Dexamethasone | — | — | — | — | 2 | ||
| Rituximab | — | — | — | — | — | 4 | |
| Sulforaphane | — | — | — | — | 3 | ||
| Daridorexant 50 mg | — | — | — | — | — | 2 | |
| Hyperbaric oxygen | — | — | — | — | 2 | ||
| Methylphenidate | — | — | — | — | — | 1 | |
| carbidopa-levodopa | — | — | — | — | — | 1 | |
| Duloxetine | — | — | — | — | — | 1 | |
| Daratumumab | — | — | — | — | — | 1 | |
| Lenalidomide | — | — | — | — | — | 1 | |
| FOLFOX | — | — | — | — | — | 1 | |
| Vitamin D3 | — | — | — | — | — | 1 | |
| CAV | — | — | — | — | — | 1 | |
| mFOLFOX6 | — | — | — | — | — | 1 | |
| Chemoradiation | — | — | — | — | — | 1 | |
| Capecitabine and Neratinib. | — | — | — | — | — | 1 | |
| Fucoidan extracted from F. Vesiculosus | — | — | — | — | — | 1 | |
| Fucoidan extracted from U. Pinnatifida | — | — | — | — | — | 1 | |
| Caffeine Citrate | — | — | — | — | — | 1 | |
| 10% povidone iodine + FV | — | — | — | — | — | 1 | |
| Rituximab Prednisone | — | — | — | — | — | 1 | |
| Vincristine | — | — | — | — | — | 1 | |
| Polatuzumab vedotin | — | — | — | — | — | 1 | |
| Ketamine hydrochloride | — | — | — | — | — | 1 | |
| Selinexor | — | — | — | — | — | 1 | |
| Indocyanine Green | — | — | — | — | — | 3 | |
| SX-682 | — | — | — | — | — | 1 | |
| Nivolumab Injectable Product | — | — | — | — | — | 1 |
11 more active programs hidden
Next readouts
- 2022-06-01
- 2024-10-29
- 2024-12-30
- 2025-04-30
- 2026-05-06
- 2026-05-30
- 2026-06
- 2026-06-01
- 2026-07-31
- 2026-07-31
Top conditions
- Cancer22
- Depression20
- Asthma18
- Parkinson Disease13
- Loneliness12
- Heart Failure10
- Insomnia10
- Breast Cancer9
Frequently asked questions about University of Rochester
- How many clinical trials does University of Rochester have on ClinicalTrials.gov?
- University of Rochester is listed as the lead sponsor on 735 clinical trials in ClinicalTrials.gov, 149 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Rochester's trials are in Phase 3?
- 28 of University of Rochester's trials are in Phase 3, spread across 51 active drug programs.
- What therapeutic areas does University of Rochester focus on?
- University of Rochester's most-studied conditions on ClinicalTrials.gov are Cancer, Depression, Asthma, Parkinson Disease, Loneliness.
- When are University of Rochester's next clinical trial readouts?
- University of Rochester has 10 upcoming primary-completion readouts tracked here; the soonest is “Neoadjuvant FOLFOX Therapy With Short Course Radiation and Active Surveillance in Locally Advanced Rectal Cancer”, expected around 2022-06-01.